Category - Markets

Piper Jaffray launched coverage of Canopy Growth (NYSE:CGC; TSX:WEED) with an “overweight” rating and $40 price target. The stock was quoted at $32.16, up $2.52, around midday on Jan 9. “While it is difficult to...

Ladenburg Thalmann launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $29 price target. The stock closed at $7.65 on Jan. 3. Millendo is a clinical-stage company focusing on the development...

Canaccord Genuity launched coverage of Chembio Diagnostics (NASDAQ:CEMI) with a “buy” rating and $9 price target. The stock closed at $5.48 on Jan. 3. “In our opinion, Chembio is an underappreciated player in the...

H.C. Wainwright initiated coverage of Synthorx (NASDAQ:THOR) with a “buy” rating and $30 price target. The stock closed at $17.38 on Dec. 31. Synthorx’s Expanded Genetic Alphabet (EGA) technology generates a modular...

Dawson James initiated coverage of ADMA Biologics (NASDAQ:ADMA) with a “buy” rating and $7 price target. The stock closed at $2.34 on Dec. 27. ADMA is focused on bringing a high-value, potent intravenous immunoglobulin...

H.C. Wainwright initiated coverage of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) with a “buy” rating and $24 price target. The stock closed at $5.26 on Dec. 24. The company’s lead compound, lenabasum, is a...

H.C. Wainwright launched coverage of NeuroMatrix (NASDAQ:NURO) with a “buy” rating and price target of $5. The stock closed at 68 cents on Dec. 24. NeuroMetrix is a healthcare technology company that has two products on...

H.C. Wainwright initiated coverage of Translate Bio (NASDAQ:TBIO) with a “buy” rating and $21 price target. The stock closed at $8.05 on Dec. 24. Translate Bio is developing treatments for diseases caused by an absence...

H.C. Wainwright initiated coverage of AnaptysBio (NASDAQ:ANAB) with a “buy” rating and price target of $126. The stock closed at $60.54 on Dec. 19. While AnaptysBio has emerged as a newcomer in the competitive field of...

H.C. Wainwright launched coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with a “buy” rating and $18. The stock closed at $5.27 on Dec. 19.